Beximco Takes Control Of Sanofi Bangladesh
Expands In Domestic Market With Deal Worth Almost $50m
Beximco has struck a deal worth nearly $50m to acquire a majority stake in Sanofi Bangladesh, allowing the firm to expand in its domestic market.
You may also be interested in...
Senior Beximco executive outlines details, including pricing nuances, of a deal with the Serum Institute of India for the supply to Bangladesh of the AstraZeneca/University of Oxford coronavirus vaccine. Will India’s neighbor also benefit from pricing adjustments?
Bangladesh’s Beximco reported double-digit growth both domestically and abroad in its financial first half, while continuing to expand in other international markets. Given its new launches and a COVID-19 vaccine distribution deal, the company remains optimistic about its future performance.
Beximco Pharmaceuticals has acquired a majority 85.2% stake in fellow Bangladeshi firm Nuvista Pharma for £18.2 million (US$25.2 million). In early October last year, Beximco entered into a non-binding memorandum of understanding with the hormone and steroid drug specialist (Generics bulletin, 13 October 2017, page 3).